Antibodies Archives

den bosch netherlands lava therapeutics cancer immunotherapy

Startup Scout 23 Nov 2018

This Biotech Arms Tumor-Busting Cells to Treat Cancer

In the medieval city of ‘s-Hertogenbosch, the Netherlands, Lava Therapeutics is developing a cancer immunotherapy that arms a rare type of immune cell called gamma delta T cells. Mission: Develop antibodies that recruit innate immune cells near tumors and activate them to kill cancer cells. T cells are immune cells that have a strong potential […]

November 23, 2018 - 3 minutesmins - By Jonathan Smith

News and Trends 31 Oct 2018

Multiple Myeloma Antibody Therapy Achieves Positive Phase III Results

An antibody therapy for the blood cancer multiple myeloma achieved positive results at Phase III, decreasing the risk of the disease getting worse and patient death by 45% in a Phase III trial. The blockbuster antibody daratumumab, developed by Janssen using a license from the Danish company Genmab, was given to patients in combination with […]

October 31, 2018 - 2 minutesmins - By Jonathan Smith

News and Trends 5 Oct 2018

Lab-Grown Antivenom Shows Potential for Curing Black Mamba Snakebite

Antivenoms could one day be made in the lab instead of in animals. Researchers from the Technical University of Denmark have neutralized black mamba venom in mice with lab-grown human antibodies for the first time. Snakebite is a serious problem, causing the deaths of around 100,000 people every year, and about three times that number […]

October 5, 2018 - 3 minutesmins - By Jonathan Smith

More News! 19 Sep 2018

Argenx Attracts Huge €250M Investment Following Positive Phase II Trial

Belgian biotech Argenx raised over €250M in public investment on the Nasdaq Stock Market after announcing positive Phase II results for its lead autoimmune drug candidate. The company now plans to progress efgartigimod, an antibody fragment inspired by llama antibodies, to Phase III trials for treatment of the autoimmune blood disease primary immune thrombocytopenia (ITP). […]

September 19, 2018 - 2 minutesmins - By Jonathan Smith

Interview 24 Jul 2018

Meet the Dutch Scientists who Invented Keytruda, “The President’s Drug”

Known for curing US President Jimmy Carter’s cancer, Keytruda continues to benefit many other cancer patients. The inventors told us their story, from the drug’s early days to their current role as executives of the biotech unicorn Aduro. Since 2014, the cancer drug Keytruda, also known as pembrolizumab, continues to be widely sought after due […]

July 24, 2018 - 6 minutesmins - By Editorial Team

News and Trends 20 Jul 2018

Belgian Biotech Completes First Trial with New Drug for Diabetic Macular Edema

Belgian biotech ThromboGenics has conducted the first clinical trial of an antibody to treat one of the world’s leading causes of vision loss. Results from the Phase I/II trial demonstrate the safety and tolerability of a new kind of antibody treatment for diabetic macular edema. The trial focused on injecting the THR-317 antibody, which is directed against […]

July 20, 2018 - 2 minutesmins - By External Contributor

News and Trends 9 Jul 2018

Swedish Alzheimer’s Treatment Slows the Disease in Phase II Trial

BioArctic, based in Stockholm, has clinical results showing its antibody treatment that targets amyloid plaques, a hallmark of Alzheimer’s disease, can slow the disease’s progression. The trial tested the antibody in 856 patients with early-stage Alzheimer’s disease with plaques of amyloid-beta protein in their brains, which is considered a common hallmark of the disease. Results taken at […]

July 9, 2018 - 3 minutesmins - By Alexander Burik

More News! 3 Jul 2018

NASA Studies How Outer Space Affects the Immune System

NASA is using an antibody assay to investigate the effect of space flight on white blood cells in astronauts on the International Space Station. The assay used by NASA measures blood levels of a part of an antibody called a free light chain, in order to reveal the levels of activity of B cells. This […]

July 3, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 3 Jul 2018

French Lupus Vaccine Ready to Move Into Phase III

Neovacs, a French biotech, has shown its lupus vaccine can be effective in treating this severe autoimmune disease. Its lupus vaccine works by stimulating the patient’s immune system to produce antibodies against a protein called IFNα that regulates the immune system and is involved in the disease. The study enrolled 185 patients around the globe […]

July 3, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 29 Jun 2018

Update: Yet Another ADC Company Makes Bank, This Time in Series B

Update (29.06.2018): NBE Therapeutics has extended its Series B fundraising round by 20M CHF (€17.3M), reaching a total of 40M CHF (€34.6M) for the round. Novo Holdings joins the Boehringer Ingelheim Venture Fund and the PPF Capital Partners Fund as a major shareholder of the Swiss biotech, which continues to develop its ADCs for improved […]

June 29, 2018 - 3 minutesmins - By Editorial Team

News and Trends 20 Jun 2018

Massive Series B Funding Could Bring Belgian Immuno-oncology Treatments Into the Clinic

iTeos Therapeutics raised €65M ($75M) to bring two of its cancer treatments into the clinic within the next one and a half years. iTeos Therapeutics, a Belgian biotech, raised what may have been the largest Series B financing round in Europe so far this year, led by MPM Capital. The funding will be used to […]

June 20, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 31 May 2018

UK Biotech Wins Major Grant to Manage Chronic Pain With Antibodies

Innovate UK has awarded a grant to Iontas to develop antibodies that block pain transmission by nerve cells in patients with chronic pain. Iontas, based in Cambridge, has been awarded a grant of £556K (€633K) from Innovate UK to develop its antibody platform, KnotBody, for therapeutic applications in chronic pain management. Iontas’ antibody approach could provide […]

May 31, 2018 - 2 minutesmins - By Alexander Burik

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us